The Roles of S100 Proteins and RAGE in Melanoma

Leclerc, Estelle

doi:10.5772/18899

Cited by 2 publications

(2 citation statements)

References 195 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon calcium binding, S100 proteins change the conformation and interact with their target proteins that regulate important cellular functions such as cell cycle, cell growth, and migration [138,139]. The role of S100 proteins in cancer is complex, as S100 proteins can have tumor promoter or suppressor effects, depending on the S100 protein and the type of cancer (reviewed in [140,141]). Many members of the S100 protein family are ligands of RAGE [142].…”

Section: S100 Proteins Familymentioning

confidence: 99%

“…In many cancers, S100A4 has been shown to stimulate tumor proliferation and metastasis [175,176]. S100A4 is a ligand of RAGE [141,152] and has been shown to stimulate metastasis in various cancer models, including melanoma, through its interaction with RAGE [158,159,177]. Herwig et al recently showed that the A375 human metastatic melanoma cell line actively secreted S100A4, which acted as an autocrine and paracrine stimulator of RAGE expression [159].…”

Section: S100a4mentioning

confidence: 99%

See 1 more Smart Citation

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract

Section: S100 Proteins Familymentioning

confidence: 99%

Section: S100a4mentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Protein and non-protein biomarkers in melanoma: a critical update

2012

View full text Add to dashboard Cite

Melanoma is the most malignant type of all skin neoplasms. Its worldwide incidence has steadily increased during the past decades, suggesting a probable melanoma 'epidemic'. Although current clinical, morphologic, and histopathologic methods provide insights into disease behavior and outcome, melanoma is still an unpredictable disease. Once in an advanced stage, it remains a disastrous affliction with scarce therapeutic options. Therefore, significant efforts need to be made in finding informative biomarkers or surrogate markers that could aid or improve early diagnosis of melanoma, its correct staging, the discrimination of other pathological conditions as well as indicate patients' prognosis or the most appropriate therapeutic regimes. Ideally these markers are secreted into body fluids and easily amenable to the design of non-invasive clinical tests. A critical view on the current debate on serologic protein markers, e.g., lactate dehydrogenase, tyrosinase, and melanoma inhibiting activity, and some selected non-protein markers, e.g., 5-S-cysteinyl-dopa and circulating nucleic acids, will be offered and novel innovative approaches currently being explored will be discussed. Special emphasis is put on the S100 family of calcium binding proteins that is more and more emerging as a potentially important group of both molecular key players and biomarkers in the etiology, progression, manifestation, and therapy of neoplastic disorders, including malignant melanoma. Notably, S100B and, possibly, other S100 proteins like S100A4 are assumed to fulfill requirements which make them strong biomarker candidates in melanoma. Moreover, S100 proteins receive attention as possible targets of therapeutic intervention moving closer to clinical impact.

show abstract

The Roles of S100 Proteins and RAGE in Melanoma

Cited by 2 publications

References 195 publications

RAGE Signaling in Melanoma Tumors

RAGE Signaling in Melanoma Tumors

Protein and non-protein biomarkers in melanoma: a critical update

Contact Info

Product

Resources

About